- Home
- AGEN vs STRO Comparison
AGEN vs STRO Comparison
Compare AGEN & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- STRO
- Stock Information
- Founded
- AGEN 1994
- STRO 2003
- Country
- AGEN United States
- STRO United States
- Employees
- AGEN N/A
- STRO N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGEN Health Care
- STRO Health Care
- Exchange
- AGEN Nasdaq
- STRO Nasdaq
- Market Cap
- AGEN 87.7M
- STRO 77.7M
- IPO Year
- AGEN 2000
- STRO 2018
- Fundamental
- Price
- AGEN $4.66
- STRO $0.70
- Analyst Decision
- AGEN Buy
- STRO Hold
- Analyst Count
- AGEN 4
- STRO 7
- Target Price
- AGEN $13.00
- STRO $3.97
- AVG Volume (30 Days)
- AGEN 1.7M
- STRO 1.4M
- Earning Date
- AGEN 08-07-2025
- STRO 08-12-2025
- Dividend Yield
- AGEN N/A
- STRO N/A
- EPS Growth
- AGEN N/A
- STRO N/A
- EPS
- AGEN N/A
- STRO N/A
- Revenue
- AGEN $99,524,000.00
- STRO $66,434,000.00
- Revenue This Year
- AGEN $12.69
- STRO N/A
- Revenue Next Year
- AGEN N/A
- STRO N/A
- P/E Ratio
- AGEN N/A
- STRO N/A
- Revenue Growth
- AGEN N/A
- STRO N/A
- 52 Week Low
- AGEN $1.38
- STRO $0.52
- 52 Week High
- AGEN $18.74
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- AGEN 49.92
- STRO 36.17
- Support Level
- AGEN $4.71
- STRO $0.76
- Resistance Level
- AGEN $5.22
- STRO $0.87
- Average True Range (ATR)
- AGEN 0.36
- STRO 0.07
- MACD
- AGEN -0.12
- STRO -0.01
- Stochastic Oscillator
- AGEN 14.76
- STRO 3.46
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.